Antibodies to Leukotriene B4 Receptor (BLTR and BLTR2)

Introduction

Leukotriene B4 (LTB4) a potent leukocyte chemoattractant, is known to promote several inflam¬matory diseases, including atherosclerosis. LTB4 promotes athero¬sclerosis by chemo¬attracting monocytes, by providing an amplification loop of monocyte chemotaxis via CCL2 production, and by converting monocytes to foam cells by enhanced expression of CD36 and fatty acid accumulation.

The effects of LTB4 in atherosclerosis are likely mediated through the high-affinity BLT-1 and the low-affinity BLT-2 receptors. Both receptors are G protein-coupled seven transmembrane domain receptors, whose genes are located in very close proximity to each other in the human and mouse genomes. The two receptors differ in their affinity and specificity for LTB4: High-affinity receptor BLT1 (BLTR, P2Y7) is specific for LTB4, whereas BLT2 (BLTR2) is a low-affinity receptor that also binds other eicosanoids. The two receptors also differ in their pattern of expression with BLT1 being expressed primarily in leukocytes, whereas BLT2 is expressed more ubiquitously. By mediating the activities of LTB4, these receptors participate both in host immune responses and in the pathogenesis of inflammatory diseases. Reduced disease severity in animal inflammatory models seen with LTB4 receptor antagonists and in mice with targeted deletion of BLT1 have revealed important roles for LTB4 and its receptors in regulating pathologic inflammation.

Antibody Panel to BLTR and BLTR2

Acris Antibodies offers a range of monoclonal antibodies to human BLTR as well as polyclonal antibodies to different epitopes of BLTR and BLTR2, respectively. The polyclonal antibodies can be used for Immunohistochemical stainings on Paraffin embedded sections and in Flow Cytometry .

Fig. 1: Immunohistochemical staining of human spleen using polyclonal antibody SP4366P.

Fig. 2: Immunohistochemical staining of human tonsil using polyclonal antibody SP4368P.

Fig. 3: Flow cytometric detection of BLTR using monoclonal antibody SM1844F conjugated to FITC.

Antibody Panel to BLTR and BLTR2

Leukotriene B4 Receptor (BLTR and BLTR2) antibody.

Literature

Hicks A, Monkarsh SP, Hoffman AF, Goodnow R Jr. Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments. Expert Opin Investig Drugs. 2007 Dec;16(12):1909-20.

Mathis S, Jala VR, Haribabu B. Role of leukotriene B4 receptors in rheumatoid arthritis. Autoimmun Rev. 2007 Nov;7(1):12-7.

Bäck M, Sakata K, Qiu H, Haeggström JZ, Dahlén SE. Endothelium-dependent vascular responses induced by leukotriene B4. Prostaglandins Other Lipid Mediat. 2007 May;83(3):209-12.

Subbarao K, Jala VR, Mathis S, Suttles J, Zacharias W, Ahamed J, Ali H, Tseng MT, Haribabu B. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol. 2004 Feb; 24(2): 369-75.

Tager AM, Luster AD. BLT1 and BLT2: the leukotriene B4 receptors. Prostaglandins Leukot Essent Fatty Acids. 2003 Aug-Sep; 69(2-3): 123-34.

Dasari VR, Jin J, Kunapuli SP. Distribution of leukotriene B4 receptors in human hematopoietic cells. Immunopharmacology. 2000 Jul20; 48(2): 157-63.

26 related products - click here to filter product result list